Filing Details
- Accession Number:
- 0001209191-12-021005
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-04-03 12:39:20
- Reporting Period:
- 2012-03-30
- Filing Date:
- 2012-04-03
- Accepted Time:
- 2012-04-03 11:39:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1406338 | Amit Sachdev | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St Cambridge MA 02139 | Svp, Corp Affairs & Pub Policy | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-03-30 | 19,062 | $18.93 | 60,170 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2012-03-30 | 26,562 | $41.01 | 33,608 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2012-03-30 | 19,062 | $0.00 | 19,062 | $18.93 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2008-08-15 | 2018-05-14 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 618 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $41.01 (range $40.59 to $41.34).
- Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
